Bausch + Lomb, a leading global eye health company, announced its first-quarter 2023 financial results. The company reported a first quarter loss of $90 million, after reporting a profit in the same period in 2022. Total reported revenues were $931 million for the first quarter of 2023, as compared to $889 million in the first quarter of 2022, an increase of $42 million, or 5 percent, according to an announcement from the company. “Bausch + Lomb delivered a strong first quarter with continued high-quality growth across all three reporting segments and in most of our significant markets around the world. Revenues grew 5 percent on a reported basis and 8 percent on a constant currency basis, driven by solid growth from several key franchises within our vision care segment, strong execution in our ophthalmic pharmaceuticals segment and increased demand for consumables, intraocular lenses and systems in our surgical segment,” said Brent Saunders, chairman and Ceo, Bausch + Lomb. Vision care segment revenues were $587 million for the first quarter of 2023, as compared to $560 million for the first quarter of 2022, an increase of $27 million, or 5 percent.

July 2023